Taiwan Advance Bio-Pharmaceutical Total Current Liabilities

As of the most recent data (June 2026), 4186.TWO shows a total current liabilities of $280M. That compares with $260M in the prior-year period — up 6.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 4186.TWO's total current liabilities is now $280M (was $260M) — a 6.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Taiwan Advance Bio-Pharmaceutical is outperforming or lagging.

Tracking 4186.TWO's total current liabilities over time shows whether Taiwan Advance Bio-Pharmaceutical is scaling, shrinking, or reshaping that part of the business. The current reading is $280M That compares with $260M in the prior-year period — up 6.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Taiwan Advance Bio-Pharmaceutical's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $280M) with ownership activity and broader fundamentals.

Taiwan Advance Bio-Pharmaceutical's total current liabilities is $280M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.